JP2024521460A5 - - Google Patents

Info

Publication number
JP2024521460A5
JP2024521460A5 JP2023576212A JP2023576212A JP2024521460A5 JP 2024521460 A5 JP2024521460 A5 JP 2024521460A5 JP 2023576212 A JP2023576212 A JP 2023576212A JP 2023576212 A JP2023576212 A JP 2023576212A JP 2024521460 A5 JP2024521460 A5 JP 2024521460A5
Authority
JP
Japan
Prior art keywords
mexiletine
hours
composition
weight
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023576212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521460A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/065917 external-priority patent/WO2022258842A1/en
Publication of JP2024521460A publication Critical patent/JP2024521460A/ja
Publication of JP2024521460A5 publication Critical patent/JP2024521460A5/ja
Pending legal-status Critical Current

Links

JP2023576212A 2021-06-11 2022-06-10 経口投与用のメキシレチンの持続放出組成物 Pending JP2024521460A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202131026198 2021-06-11
IN202131026198 2021-06-11
PCT/EP2022/065917 WO2022258842A1 (en) 2021-06-11 2022-06-10 Extended-release compositions of mexiletine for oral administration

Publications (2)

Publication Number Publication Date
JP2024521460A JP2024521460A (ja) 2024-05-31
JP2024521460A5 true JP2024521460A5 (https=) 2025-03-11

Family

ID=82258238

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023576212A Pending JP2024521460A (ja) 2021-06-11 2022-06-10 経口投与用のメキシレチンの持続放出組成物

Country Status (11)

Country Link
US (1) US20240173272A1 (https=)
EP (1) EP4351549A1 (https=)
JP (1) JP2024521460A (https=)
CN (1) CN117858702A (https=)
AU (1) AU2022288145A1 (https=)
BR (1) BR112023025925A2 (https=)
CA (1) CA3221594A1 (https=)
CL (1) CL2023003702A1 (https=)
CO (1) CO2023017619A2 (https=)
MX (1) MX2023014773A (https=)
WO (1) WO2022258842A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD146547A5 (de) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
CN101032462A (zh) 2006-12-20 2007-09-12 浙江大学 盐酸美西律缓释制剂及制备方法
WO2010149760A2 (en) 2009-06-24 2010-12-29 Shire Llc Mexiletine amino acid and peptide prodrugs and uses thereof
US20120196933A1 (en) 2010-12-23 2012-08-02 Richard Franklin Mexiletine prodrugs

Similar Documents

Publication Publication Date Title
US11266598B2 (en) Orally administered corticosteroid compositions
US20250144112A1 (en) Suspension for oral administration comprising amorphous tolvaptan
TWI222879B (en) Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder
EP2561892B1 (en) Easily dosable solid preparation
US9789068B2 (en) Easily dosable solid preparation
CN1447694A (zh) 快速起效制剂
TWI835118B (zh) 布瑞哌唑口溶膜組合物、其製備方法及用途
KR102479497B1 (ko) 바레니클린 서방성 제제 및 이의 제조 방법
CN1398184A (zh) 具有改善的生物利用度和缩小的个体内和个体间吸收差异的含有伊曲康唑的组合物
JP2026062756A (ja) ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
WO2021129735A1 (zh) 一种固体制剂及其制备方法和用途
TW200911303A (en) Powders for reconstitution
JP2002537323A (ja) ロラタジン及びプソイドエフェドリンを含有する医薬カプセル組成物
JP2024521460A5 (https=)
EP3331502B1 (en) Controlled release propiverine formulations
WO2021254409A1 (zh) 一种复合物的药物组合物及其制备方法
WO2025142803A1 (ja) Ｄｎｍｔ阻害剤の経口投与用の医薬組成物
ES2228789T3 (es) Composicion oral de tramadol en forma de granulados para tomar una vez por dia.
JP2024512069A5 (https=)
CN118045064B (zh) 一种地氯雷他定口溶膜组合物、其制备方法及应用
CN117919370A (zh) 一种拟肽类化合物的药物组合物及其用途
HK40096982A (zh) 包含美洛昔康的医药组成物
JP2009507850A5 (https=)
TW202537624A (zh) 布南色林口溶膜組合物、其製備方法及用途
CN116437902A (zh) 包含美洛昔康的医药组成物